An observational study in Leukemia, sponsored by ECOG-ACRIN Cancer Research Group. Completed. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by ECOG-ACRIN Cancer Research Group · Observational
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at tissue samples from patients with T-cell acute lymphoblastic leukemia.
OBJECTIVES:
OUTLINE: This is a multicenter study.
Frozen lymphoblast samples from patients with T-cell acute lymphoblastic leukemia (NOTCH1-mutated and wild type) are assessed for genetic expression profiles and mutations by microarray analysis and activated NOTCH1 protein by western blot analysis.
PROJECTED ACCRUAL: A total of 48 samples from patients will be accrued for this study.
5,442 studies on the registry are indexed under Leukemia; 637 are open to participants now.
This study's enrollment of 49 is below the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →ECOG-ACRIN Cancer Research Group is the lead sponsor of 118 studies on the registry; 13 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Samples submitted for research from patients participating in E2993
DISEASE CHARACTERISTICS:
Frozen lymphoblast samples available
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Exclusion Criteria:
Transcriptional signatures associated with NOTCH1 mutations in T-cell acute lymphoblastic leukemia (T-ALL) cells
Mutational analysis
Time frame: 1 month
Global changes on gene expression resulting from inactivation of NOTCH signaling in T-ALL cells
Gene expression
Time frame: 1 month
No study locations are listed for this record.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ECOG-ACRIN Cancer Research Group